科拓生物(300858) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥86,068,078.55, representing a 6.63% increase compared to ¥80,716,575.97 in the same period last year[3] - Net profit attributable to shareholders was ¥23,445,594.81, an increase of 8.75% from ¥21,558,322.68 year-on-year[3] - Total operating revenue for Q1 2022 was CNY 86,068,078.55, an increase of 6.7% compared to CNY 80,716,575.97 in Q1 2021[23] - Net profit for Q1 2022 reached CNY 23,445,594.81, representing a growth of 8.8% from CNY 21,558,322.68 in Q1 2021[24] - The company achieved a total profit of CNY 28,031,886.15 in Q1 2022, compared to CNY 25,835,238.25 in Q1 2021, indicating an increase of 8.4%[24] Cash Flow - The net cash flow from operating activities reached ¥36,584,759.23, showing a significant increase of 91.43% compared to ¥19,110,813.82 in the previous year[3] - Operating cash flow for Q1 2022 was CNY 36,584,759.23, significantly higher than CNY 19,110,813.82 in Q1 2021, indicating improved cash generation[26] - Cash inflow from operating activities totaled CNY 110,404,760.68 in Q1 2022, down from CNY 125,004,472.30 in Q1 2021[26] - The net cash flow from investment activities was -236,853,601.57 CNY, compared to a positive cash flow of 99,365,015.00 CNY in the previous year[28] - The net increase in cash and cash equivalents for the quarter was -200,392,800.84 CNY, compared to an increase of 118,475,828.82 CNY in the same period last year[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,063,165,160.19, a 2.16% increase from ¥1,040,729,235.00 at the end of the previous year[3] - Total current assets were CNY 718,361,995.97, down from CNY 752,589,813.41, indicating a decrease of about 4.5%[20] - The company's accounts receivable stood at CNY 100,564,442.48, down from CNY 115,087,170.46, reflecting a decrease of approximately 12.7%[19] - Total liabilities decreased to CNY 71,015,536.93 in Q1 2022 from CNY 73,332,468.79 in Q1 2021, a reduction of 3.2%[22] - Non-current assets totaled CNY 344,803,164.22, up from CNY 288,139,421.59, showing an increase of approximately 19.6%[20] Shareholder Information - The company approved the grant of 324,000 restricted stock units to six incentive targets on January 27, 2022[17] - The total number of shares held by the top ten unrestricted shareholders includes 2,999,940 shares held by China Ping An Life Insurance Co., Ltd.[16] - The company reported a total of 95,437,413 shares under lock-up agreements as of the end of the reporting period[16] - The company plans to lift the lock-up on certain shares on July 27, 2023, affecting 62,000,000 shares held by specific shareholders[15] Other Financial Metrics - Basic earnings per share rose to ¥0.16, up 6.67% from ¥0.15 in the same quarter last year[3] - The weighted average return on equity was 2.39%, slightly up from 2.29% in the previous year[3] - Research and development expenses increased to CNY 7,635,949.69 in Q1 2022, compared to CNY 6,362,429.11 in Q1 2021, marking a rise of 20%[23] - The company reported a total of ¥3,890,686.95 in non-recurring gains and losses, primarily from government subsidies and fair value changes of financial assets[5] - Cash and cash equivalents decreased to CNY 281,430,579.21 from CNY 481,823,380.06, representing a decline of approximately 41.7%[19]